Filter by: patients
Home > Community Treatment Reports and Side Effects > RA Phase 2-3 Study Tasocitinib (CP-690,550) Treatment Report
What is RA Phase 2-3 Study Tasocitinib (CP-690,550)?

NCT00413699 is a long-term, open-label follow-up study of tasocitinib (CP-690,550) for treatment of rheumatoid arthritis. Other study IDs include: A3921024.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
RA (Rheumatoid Arthritis) 2 1 Efficacy_major

See all 2 patients currently using RA Phase 2-3 Study Tasocitinib (CP-690,550)

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 0
Mild
 0
None
 1

Reported Schedules

  20 mg daily
  2 Number of Patients: 2  

Reported Duration See details about how long patients take this treatment ▼

Currently Using RA Phase 2-3 Study Tasocitinib (CP-690,550)

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of RA Phase 2-3 Study Tasocitinib (CP-690,550)

Always
 1 100%
Usually
 0 0%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of RA Phase 2-3 Study Tasocitinib (CP-690,550)

Very
 0 0%
Somewhat
 0 0%
A little
 0 0%
Not at all
 1 100%

Cost

Paid out of pocket

Cost of RA Phase 2-3 Study Tasocitinib (CP-690,550)

$200+
 0 0%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 0 0%
< $25
 1 100%

Report created on May 24, 2012.